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Abstract
Feline Leukemia Virus (FeLV) is a retrovirus that affects domesticated cats and other
species in the Fe/is genus. There are three major subtypes, each characterized by unique
disease progression and proviral sequences. FeLV-A is weakly pathogenic, -B has been
associated with tumors, and -C causes severe anemia. Proviral sequences were amplified
using PCR with FeLV-specific and adapter-specific primers. The method of primer
walking has yielded consensus sequences for several fragments of 1,000-3,000 base pairs
of proviral DNA. Sequences for ten different clones of the provirus envelope region from
a FeLV positive blood sample were compared to known sequences and revealed novel
insertions.
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Introduction
Feline Leukemia Virus (FeLV) is a gammaretrovirus that affects domestic cats
(Fe/is catus) and closely related species which causes hematological diseases such as

lymphoma, leukemia, and severe anemia 1 1•31. It is widely believed that FeLV originated
from a trans-species infection of a rodent inflicted with a gammaretrovirus that, after
consumption of the mouse by the ancestral cat, resulted in FeLV 141. Other species that
have recently been found to be infected with FeLV include the Florida panther and the
endangered Iberian lynx 141. FeLV has also been of significant platform for human
research as well; the T-cell lymphomas described in FeLV-positive cats inspired US
biomedical researchers to investigate human T-cell leukemia, and eventually these
studies culminated in the discovery of human immunodeficiency virus type 1 141.
There are primarily three different major subgroups of FeLV that are
differentiated by the receptor the virus uses to enter the cell as well as its host range; the
most common subgroup is FeL V-A 1 1, 4, 51. FeLV-A is responsible for horizontal
transmission between animals and gives rise to other FeLV subgroups 14• 51. FeLV-A
utilizes the thiamine transporter THTRI to integrate into host cells 141. It was previously
thought that FeLV-A subgroups could be generalized as weakly pathogenic, but recent
research into sequence variation of FeL V-A has discovered that subtle mutations have
brought about a strain, FeLV-945, of FeLV-A that produced greater pathological
consequences for infected cats l31.
The two other major subgroups of FeLV include FeL V-8 and FeLV-C. FeLV-8
is associated with tumor formation and lymphoma, and arises from recombination events
between FeLV-A and endogenous FeLV that is already present in the host genome 151.
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FeLV-B utilizes the phosphate symporter Pit-I and the closely related Pit-2 as receptors
for viral integration 141. It is widely believed that FeLV-A is necessary for transmission of
FeLV-B and FeLV-C, but there has recently been an example of host transmission of
FeLV-B in the absence of FeLV-A 16, 71. FeLV-C is associated with red blood cell aplasia
and severe anemia that is fatal within weeks, and binds to the heme transporter FLVCRI
for viral integration into the host cell 141. The exact genesis of the FeLV-C subgroup is
unknown, but is thought to be arisen through recombination or possibly through
mutational changes in FeLV-A 14, 81. There are two other subgroups of FeLV, FeLV-T and
FeLV-D, that have yet to be well defined; FeLV-T has been found to be similar to FeLV
AIDS and is thought to arise via mutation, and FeLV-D arose through recombination
with FeLV-A and endogenous FeLV, similar to that ofFeLV-B 15• 81.
FeLV is a simple retrovirus and therefore only encodes for genes that are required
for its structure and replication 1 1 1. The three viral genes that make up the FeLV genome
are the gag, pol, and env genes (Figure 1) 121. The gag gene encodes for structural proteins
including the capsid of the virus, the pol gene encodes for replicating enzymes, and the

env gene encodes for the surface glycoprotein (SU) and the transmembrane protein (TM)
which make up the viral envelope 121. The differences in subtype therefore arise through
mutations within the env region, and these mutations are often caused in vivo during
FeLV replication due to the low-fidelity ofreverse transcriptase (IJ. The envelope is also
responsible for the entry of the retrovirus into host cells as the SU protein, attached to the
TM, interacts with host cell surface receptors £51.
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Figure 1: Viral E11velope Structure ofSurface Glycoprotein. The structure of the
integratedFeLV provirus, including the viral genes (gag, pol, env) and the long terminal
repeat (LTR). An enhanced section of the env gene is brought forward to illustrate the
location of Variable Region A (VRA) and Variable Region B (VRB) that construct the
RBD. Differences within these regions affect cellular tropism and pathogenicity as the
virus integrates into the host cell.
Within the SU protein are two highly variable domains that are integral for
interaction and entry to host cells: Variable Region A (VRA) determines receptor binding
and host range, and Variable Region B (VRB) is required for efficient infection 121.
Adjacent to these two variable regions is the Proline Rich Region (PRR) that mediates
conformation changes required for viral entry l21. These three domains together are
referred to as the Receptor Binding Domain (RBD) l21. Variations then in the RBD of the
SU protein are then of considerable interest as these mutations are thought to influence
the rate of viral infection and therefore the resulting pathology of the disease l21.
SinceFeLV is a simple gammaretrovirus, and therefore only encodes for genes
required for structure and replication, there are no genes within the genome of FeLV that
are directly malignant [41. Instead, the association ofFeLV with tumors and malignancies
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arises from the integration ofproviral DNA into the host genome and activating
oncogenes l41. This oncogene activation is not necessarily targeted by the proviral
integration, but certain genomic loci ofhost cells have been determined to be common
insertion sites in which FeLV integrates and causes the activation ofoncogenes at a rate
greater than random chance l41. FeLV also may undergo a process referred to as retroviral
transduction in which endogenous oncogene sequences are incorporated into the viral
genome and are then able to infect other host cells through FeLV replication and
integration £41.
The goal ofthis project was to identify mutational changes in the env gene from
the blood ofa FeLV-positive cat. Proviral sequences from a FeLV -positive kitten were
amplified using PCR with FeLV-specific and adapter-specific primers. The method of
primer walking has yielded consensus sequences for several fragments of 1,000-3,000
base pairs ofproviral DNA. Through this, novel substitutions and insertions were found
in the proviral clones that were located within the PRR and VRB ofthe RBD that may
consequently have affected pathogenicity ofthe FeLV virus.
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Materials and Methods
Extraction of Genomic DNA from Blood Samples
A Nucleospin Tissue Genomic DNA Extraction Kit (Clontech) was used to
extract blood and tissue samples.

Preparation of Blood Lysates
Blood samples were lysed by pipetting 25 µL proteinase K and 200 µL whole or
EDTA anti-coagulated blood into 1.5 mL microcentrifuge tubes. A volume of200 µL
Buffer B3 was added to the samples, which were then vortexed vigorously ( I 0-20 s).
Following incubation at room temperature for 5 min, the samples were vortexed gently,
and then incubated at 70 °C for 10-15 min.

Binding, Washing, and Eluting DNA from Blood Lysates
Blood and tissue lysates were vortexed briefly after incubation, then µL ethanol
(96-100 %) were added. Samples were then vortexed vigorously, and transferred to a
NucleoSpin® spin column and collection tube. After centrifuging for 1 min at 11,000 x g,
the flow-through was discarded, and 500 µL Buffer BW were added. The tubes were
again centrifuged for 1 min at 11,000 x g, and the flow-through was discarded. An aliquot
of600 µL Buffer 85 was added, the columns were again centrifuged for 1 min at 11,000
x g, and the flow-through was discarded. The columns were then centrifuged for 1 min at
11,000 x g to remove residual ethanol. The dry spin columns were then placed in clean
collection tubes. Elution Buffer BE was pre-incubated at 70 °C, then a volume of 50 µL
was added to each sample. After incubation at room temperature for 3 minutes, samples
were centrifuged for 1 min at 11,000 x g to collect DNA eluent. The spin columns were
placed in clean collection tubes, and a second aliquot of 50 µL Elution Buffer BE was

6

added to each sample. After 3 minutes at room temperature, the samples were again
centrifuged for 1 min at 11,000 x g. All samples were then stored as recommended at -20
�C until used.

Preparation of DNA Libraries
Restriction Enzyme Digestion

DNA templates were digested with restriction enzymes Oral, EcoRV, Pvull, and
Stul according to the Genome Walker manual (Clontech). For each digestion, 25 µL of
DNA extract were mixed with 8 µL ofrestriction enzyme (10 units/µL), 10 µL of buffer
( I Ox), and 57 µL of deionized water. The tubes were inverted several times to mix, and
incubated at 37 °C for 2 hours. After vortexing gently for 10-15 s, the reactions were
incubated overnight at 37 °C.
Post-Digestion Purification

A NucleoSpin® Gel and PCR Clean-up Kit )Clontech) was used to purify the
digested DNA samples. Spin columns were placed into collection tubes (2 mL) and 500700 µL of sample digest were loaded. The column was centrifuged for 30 s at 11,000 x g,
and the flow-through was discarded. A volume of700 µL Buffer NT3 was added, and the
column was centrifuged for 30 s at 11,000 x g. The flow-through was discarded and the
column centrifuged again for I min at 11,000 x g to remove Buffer NT3 completely, and
were then incubated for 5 min at 70 °C. The columns were then placed into new 1.5 mL
microcentrifuge tubes, and 30 µL Buffer NE were added. After incubating at room
temperature for 1 min, tubes were centrifuged for 1 min at 11,000 x g, and the eluent was
collected. Samples were stored at -20 °C until used.
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Ligation of Adapter Sequences to Purified DNA Digests
Adapters were ligated to each sample of purified DNA digest using reagents from
and according to the instructions in the Genome Walker kit (Clontech). The reaction
mixture was composed of4.8 µL purified DNA digest, 1.9 µL Genome Walker Adaptor
(25 µM), 0.8 µL of lOx Ligation Buffer, and 0.5 µL T4 DNA Ligase (6 units/µL).
Samples were incubated at 16 °C overnight in a thermal cycler, then incubated for 5 min
at 70 °C to stop the reaction. To each tube, 32 µL ofTE buffer (10/1 pH 7.5) were added.
The tubes were vortexed gently for 10-15 s, and then stored at -20 °C until used.
[Mg2+11 mM
BlR:GGTCCAAlTGAGCACCGCCATGGAAA

65.9

183R: CGGCTAGATAGTGCGCCCCTGTATGT

65.8

PCR Reactions
Master mixes for primary and secondary PCR were prepared by combining
reagents as shown in Table l , for the appropriate number of total reactions. After mixing,
24 µL were added to each PCR reaction tube, along with 1 µL of template, or PCR-grade
water for negative controls. Reaction conditions for primary and secondary PCR are
shown in Table 2.
Table 1. Reagents for each primary or secondary PCR reaction.
19.5 µL

PCR-Grade Water

2.5 µL

lOx Advantage 2 PCR Buffer

0.5 µL

dNTP (10 mM each)

0.5 µL

Each primer (10 µM)

0.5 µL

Advantage 2 Polymerase Mix (50x)
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Table 2. Reaction conditions for primary and secondaryPCR.
SecondaryPCR

PrimaryPCR
7 Cycles

32 Cycles
1 Cycle

Step I

94°c

25 sec

Step2

12 °c

3 min

Step3

94°c

25 sec

Step4

67°C

3 min

Step5

67 °C

7 min

5 Cycles
20 Cycles
I Cycle

Step I

94°c

25 sec

Step2

12 °c

3 min

Step3

94,;,c

25 sec

Step4

67°C

3 min

Step5

67°C

7 min

The gene-specific primers used for PCR were designed using NCBI Primer Blast.
For primary and secondary PCR, the primer sequences were 5' GGTCCAATTGAGCACCGCCATGGAAA-3' and5'CGGCTAGATAGTGCGCCCCTGTATGT-3 ', respectively. Both forward primers were supplied
with the Genome Walker kit (Clontech).

Purification of PCR Amplicons
A NucleoSpin® Gel and PCR Clean-up kit (Clontech) was used for purification
of PCR products and the extraction of bands from agarose gels.
DNA Extraction from Agarose Gels

A scalpel was used to excise the DNA fragment from an agarose gel, and all
excess agarose was removed. The gel slice was weighed and transferred to a clean 1.5
mL tube. For each 100 mg of agarose gel, 200 µL of Buffer NTI was added. The samples
were incubated for 5-10 min at 50 °C. The sample was vortexed briefly every 2-3 min
until the gel slice was completely dissolved.
Post-PCR Clean-Up

A NucleoSpin® Gel and PCR Clean-up Column was placed into a collection tube
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(2 mL) and up to 700 µL of sample was loaded and centrifuged for 30s at 11,000 x g. The
flow-through was discarded and the column was placed back into the collection tube. The
remaining samples were loaded and the centrifugation step repeated. A volume of 700 µL
Buffer NT3 were added to the column, which was then centrifuged for 30 s at 11,000 x g.
The flow-through was discarded and the column placed back into the collection tube. The
column was centrifuged for 1 min at 11,000 x g to remove Buffer NT3 completely. The
column was then placed into a new 1.5 mL microcentrifuge tube, and 30 µL Buffer NE
were added. The column was incubated at room temperature for 1 min, and the tube was
centrifuged for 1 min at 11,000 x g to collect the eluent.

Cloning and Transformation
Cloning was performed using a TOPO-TA Cloning Kit for Sequencing. Briefly, 2
µL of PCR product was mixed with 1 µL of Salt Solution, 2 µL of water, and I µL of
pCR-4-TOPO vector. Reactions were incubated at room temperature for 20-30 minutes,
then placed on ice for transformation into One Shot DH5a -Tl chemically competent
cells. Each vial of cells was thawed on ice for 5 minutes before adding 2 µL of a cloning
reaction. Vials were incubated on ice for 20-30 minutes, heat shocked at 42 °C for 30
seconds, and placed back on ice for the addition of 250 µL of S.O.C. medium. Tubes
were then shaken for 1 hour at 200 rpm and a temperature of 37 °C. Colonies were grown
on LB plates with either ampicillin or kanamycin, then cultured overnight in LB medium
for extraction.

Plasmid Extraction
A PureLink® Quick Plasmid Miniprep Kit was used to isolate plasmid DNA.
Harvesting was accomplished by centrifuging 5 mL of overnight LB-culture. All medium
10

was removed. A volume of250 µL Resuspension Buffer (R3) with RNase A was added
to the cell pellet and the pellet was resuspended until it is homogeneous. A volume of 250
µL Lysis Buffer (L7) was added and the solution was mixed gently by inverting the
capped tube until the mixture was homogeneous. The tube was incubated at room
temperature for 5 minutes, then 350 µL Precipitation Buffer (N4) was added. The
solution was mixed immediately by inverting the tube, or for large pellets, vigorously
shaking the tube, until the mixture was homogeneous. The lysate was centrifuged at
12,000 x g for 10 minutes.
The supernatant was loaded onto a spin column in a 2-mL wash tube and
centrifuged at 12,000 x g for 1 minute. The flow-through was discarded. Another wash
was done by adding 500 µL Wash Buffer (WI 0) with ethanol to the column, allowing the
column to incubate at room temperature for 1 minute, then centrifuging at 12,000 x g for
1 minute. The flow-through was discarded, and 700 µL Wash Buffer (W9) with ethanol
was added to the column, which was then centrifuged at 12,000 x g for 1 minute. The
flow-through was discarded, and the column was centrifuged again 12,000 x g for 1
minute. The spin column was placed in a clean 1.5-mL recovery tube. A volume of 75 µL
of preheated (70 °C) TE Buffer (TE) was added to the center of the column, which was
incubated for 1 minute at room temperature, then centrifuged at 12,000 x g for 2 minutes
to elute the purified plasmid DNA. The plasmid DNA was stored in aliquots at -20°C
until used.

Sequencing
Samples were submitted for standard Sanger sequencing at the University of
Michigan Core Sequencing Lab.
11

Results and Discussion
Two amplicons containing proviral envelope sequences were isolated from an
agarose gel following secondary PCR (Figure 2). The lane in Fig.2 shows two DNA
bands blocked in red and blue boxes of approximately 1 000 and 3000 base pairs,
respectively. These gel bands were then extracted, cloned and transformed. Five colonies
were isolated and sequenced. After consensus sequences were determined using
sequencing chromatograms, these clones were then compared to
known sequences found through relevant literature and the NCBI
website (Figure 3). The alignment in Fig. 3 was constructed using
ClustalX software. Refer to Appendix A for all clonal consensus
sequences. An important note are the large insertions which are
typically characteristic ofFeLV-B envelope sequences as
recombination events occur between FeLV-A and endogenous FeLV.
It is with interest then, as illustrated by arrows in Figure 3, Clones

Figure 2: Gel Image ofAmp/icons from Secondary PCR on
Extracted Genomic DNA/rom FeLV-Positive Cat. These gel bands
were extracted for clonal generation. Band A (indicated by red box)
is the source of Clones A l , A2, A3, A4, and AS. Band B (indicated
by blue box) is the source of Clones B l , 82, 83, 84, and 85. Due to
their differences in size, this indicates that Clones A l through AS
were smaller in size than Clones B 1 through 85, and therefore Band
B clones were longer in DNA sequence.
B 1 , 82, and 83 had a novel insertion. However, this insertion was
not found in any of the other known sequences ofFeLV, including
FeLV-B. The position ofthese insertions was found to be located in the PRR ofthe RBD.
This then may have affected the way these particular clones would enter its host cell via
the virus' conformational changes. The resulting efficiency (or inefficiency) of viral
12
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Figure 3: DNA Seque11ce Alignme11t ofProviral
FeL V Clones a11d Reference Sequences. Envelope
sequences of reference FeLV sequences were used
to align with consensus sequences of clonal DNA
generated throughout the experiment. FeLV-A:
Ml 8248, AYF052723, EU359306, EU359307,
EU359308, EU359309, M12500. FeLV-8:
K01208. K01209, EU783973, J03448.l. FeLV-C: Ml4331. FeLV-T: M87886.
FeLV-fAIDS: Ml 8247. Murine Leukemia Virus: Z l 1128, 094692. Black arrows
indicate locations of novel insertions within proviral clones. Asterisk stars
indicate consensus base pair across all sequences.
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integration and entry based on these insertions could then change resulting pathology of
the virus.
Another insertion was detected in Clone 82 within the VRB of the RBD (Figure
3). As illustrated, this insertion was not seen in any of the other clones or known
sequences. VRB determines efficient infection of the virus and therefore this insertion
may affect this efficiency of resulting infection. However, the insertion also causes a
frame-shift mutation, which will likely cause a nonfunctional clone of the FeLV, due to
the dramatic change in downstream amino acid sequence.
Due to these novel insertion sites, clones of interest were then compared to
predicted protein structures of known envelope sequences of FeLV -A, -8, and -C
subgroups (Figure 4). The distinct structure of each envelope structure follows the pattern
of each subgroup utilizing different receptors and the usage of receptor differentiation to
determine subtype l21. Though structure may vary slightly, the general structure between
strains within the FeLV-A subgroup would likely be extremely similar as FeLV -A has a
>97% amino acid similarity within the envelope gene despite geographical location or
reverse transcriptase infidelity l21. Predicted protein structures were constructed using
RaptorX software for each clone; RaptorX uses amino acid sequences associated with
known protein secondary structure to predict the secondary structure of the submitted
input l91. Clones A l through A5 were not included in this report due to their small length
in amino acid sequence past the envelope open reading frame (ORF) for translation.
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Figure 4: Predicted Envelope Protein Structures ofKnown FeLVSubtypes. (A) The
structure of Rickard-A envelope sequence, a FeLV-A strain. (B) The structure of
Gardner-Arnstein envelope sequence, a FeLV-B strain. (C) The structure of Sarma
envelope sequence, a FeLV-C strain. These three predicted protein structures are
included for comparison to notable predicted protein structure of Clones.
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Clone 82's unique insertion was observed in a 3D secondary protein structure
(Figure 5). It was compared to FeLV-A, the Rickard strain, due to the close homology of
this clonal sequence to the A subgroup. As shown, the insertion caused a loss of
secondary structure beta sheet. Due to the insertion's critical location within the RBD, it
is likely that this loss of structure is indicative of a loss of function mutation as well
within clone 82.

Figure 5: Novel Insertion Causes Loss ofSecondary Structure. Above are 3D images of
the predicted envelope protein domain l structure of the Rickard A FeLV strain (left) and
Clone 82 (right). Red boxes indicate the area in which the insertion was located. As seen
in Clone 82, this insertion caused loss of beta sheet structure which may affect binding
and efficient infection to host cells.
Clone B3 was selected as a representative to view the predicted protein structure
due to its larger consensus amino acid sequence than Clone 81; Clone 82 was not
selected due to its :frameshift mutation (Figure 6). The arrow within the figure draws
attention to the location of the four amino acid insertion site. Though this is in a predicted
unstructured area of the protein, it should be noted that this insertion still lies within the
PRR and therefore could affect conformational changes of the viral entry as well as
antibody/antigen interactions.
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After examining individual clonal envelope structure, the evolutionary
relationship between all clonal DNA sequences was compared to known sequences by

Figure 6: C/011e B3 Predicted Envelope SU Protein Structure. Above is the full

predicted protein structure of the envelope of Clone 83. The blue arrow indicates the
general location ofwhere the novel insertion occurred. Though there is no noticeable
secondary structure, this insertion is within the PRR and can affect conformational
changes during viral fusion to host cell. Other changes in PRR sequence have been
shown to affect antigen/antibody binding which suggests this insertion to Clone 83 could
influence immunological responses from the host against infection.
constructing a phylogenetic tree (Figure 7). The outgroups for this phylogenetic tree were
the murine leukemia virus and the friend murine leukemia virus which are distantly
related to FeLV; the murine leukemia virus is believed to be the ancestral virus from
which FeLV developed 141. All FeLV-8 subtypes were grouped together on the bottom
branch (Fig. 7) after a divergence event from the FeLV-A subgroup. The FeLV-C strain
(Ml 4331) was shown to branch off on its own with slightly less divergence from FeLV A subtype than the divergence between FeLV-8 and FeLV-A. One FeLV-T strain
(M87886) and one FeLV-FAIDS strain (M18247) are closely connected to one another
which supports the evidence that suggests the close relationship both genetically and
pathologically between FeL V-T and F AIDS 15• 81. The other reference sequences are
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strains within the FeLV-A subgroup. As shown in Fig. 7, these A subgroup strains have
minor divergence events, but remain clustered together. Clones A l -5 and Clones B 1-5
however show close relation, but divergence, from all FeLV-A subgroups. Particularly,
Clones B 1-3, which all include the novel insertion in the PRR, are shown to be most
closely evolutionary related to each other out ofall 10 total clones. This divergence from
the A subgroup may be indicative ofa stronger departure from the FeL V-A sequence
which typically has >97% amino acid sequence identity 131. The consequences ofthis
difference could be comparable to that ofFeLV-945 which had a greater pathogenic
effect on its host cell due to a possible increase in its binding affinity or integration
kinetics 131.
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Figure 7: Phyloge11etic Tree ofKnown FeL VSequences in Relation to Proviral Clones.
This tree was completed with maximal parsimony using Seaview after alignment with
ClustalX. FeLV envelope DNA sequences were randomized five times and bootstrapped
1000 times. Clones were closest in evolutionary relation to the FeLV-A reference
sequences. The bottom branch contains FeLV-B subgroup. FeLV-C is scattered
throughout as the sequence consistency ofthe -C subgroup is low. The outgroups used
were envelope sequences ofthe murine leukemia virus and friend leukemia virus.
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Conclusions and Future Directions
Novel insertion sites have been detected in Clones B 1-3 that are located within
the receptor binding domain of the FeLV envelope region. Due to the location of these
insertions, pathology of the resulting viral progression may be affected; this may suggest
why Cat 28-the source of the samples used in this project-died at such a young age from
a subgroup most closely resembling FeLV-A which is typically weakly pathogenic.
Future directions of this project include screening other blood and tissue samples
from the original population at a feline leukemia cat rescue to obtain live virus which will
be required for further viral assays. Though Cat 28 died as a kitten, the mother was also
FeLV-positive and may have horizontally transmitted the same or very similar strains of
FeLV to other cats. If the viral insertions are not found from sample screening of similar
cats, an alternative route to obtaining live virus would be to genetically modify the
samples collected using CR1SPR/Cas9 technology in order to recreate the insertions
found in this experiment cio1. Once live virus has been collected, a viral interference assay
could then be performed in order to accurately determine the subtype of the FeLV strain
l 1 1 1. Other future experiments should include a cell binding assay that will analyze viral
integration of the clones into host cells to examine binding affinity and kinetics l 121. This
will be of interest due to the insertions being located within the receptor binding domain
of the FeLV. A neutralizing antibody assay should also be conducted to analyze the
possible effects of the insertion on antibody-antigen interactions and therefore
immunological response of the infected host l61.
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Appendix A
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Clone Al Consensus Sequence
GCGTGGTGGAATCCCACCTCCTCATGGGATTATATCACAGTAAAAGGAGGGA
GTAGTCAGGACAATAGCTGCGAGAGAAAATGCAACCCCCTAGTCTTACAGTT
CACCCAGAAGGGAAGACAAGCCTCTTGGGACGGACCTAAGATGTGGGGATT
ACGACTATACCGTACCGGATATGACCCTGTCACTTTATTCACGGTGTCCCGGC
AGGTATCAGCCATCACGCCGCCTCAGGCAATGGGACCAAACCTAGTCTTACC
TGATCAGAAACCCCCATCCCGACAATCTCAAACAGAGTCCAAAGTGGCAACC
CAGAGGCCCCAAACGAATACAAGTACCCCAGGGTCTGTTGCCCCCGCCACCA
TGAGTCCCAAACGGATTGGGACCGGAGATAGGTTAATAAATTTAGTGCAAGG
GGCATACCTAGCCTTAAATGCCACCGACCCCAACAAAACTAAAGACTGTTGG
CTCTGCCTAGTTTCTCGACCACCCTATTACGAAGGGATTGCAATCTTAGGTAA
CTACAGCAACCAAACAAACCCCCCCCCATCCTGCCTATCTACTCCGCAACAT
AAACTAACTATATCTGAGGTATCGGGGCAAGGACTGTGCATAGGGACTGTTC
CTAAGACCCACCAGGC
Clone A2 Consensus Sequence
GCGTGGTGGAATCCCACCTCCTCATGGGATTATATCACAGTAAAAAGAGGGA
GTAGTCAGGACAATAGCTGCGAAAGAAAATGCAACCCCCTAGTCTTACAGTT
CACCCAGAAGGGAAGACAAGCCTCTTGGGACGGACCTAAGATGTGGGGATT
ACGACTATACCGTACCGGATATGACCCTGTCACTTTATTCACGGTGTCCCGGC
AGGTATCAGCCATCACGCCGCCTCAGGCAATGGGACCAAACCTAGTCTTACC
TGATCAGAAACCCCCATCCCGACAATCTCAAACAGAGTCCAAAGTGGCAACC
CAGAGGCCCCAAACGAATACAAGTACCCCAGGGTCTGTTGCCCCCGCCACCA
TGAGTCCCAAACGGATTGGGACCGGAGATAGGTTAATAAATTTAGTGCAAGG
GACATACCTAGCCTTAAATGCCACCGACCCCAACAAAACTAAAGACTGTTGG
CTCTGCCTAGTTTCTCGACCACCCTATTACGAAGGGATTGCAATCTTAGGTAA
CTACAGCAACCAAACAAACCCCCCCCATCCTGCCTATCTACTCCGCAACATA
AACTAACTATATCTGAGGTATCGGGGCAAGGACTGTGCATAGGGACTGTTCC
TAAGACCCACCAGG
Clone A3 Consensus Sequence
AATCCCACCTCCTCATGGGATTATATCACAGTAAAAGGAGGGAGTAGTCAGG
ACAATAGCTGCGAAAGAAAATGCAACCCCCTAGTCTTACAGTTCACCCAGAA
GGGAAGACAAGCCTCTTGGGACGGACCTAAGATGTGGGGATTACGACTATAC
CGTACCGGATATGACCCTGTCACTTTATTCACGGTGTCCCGGCAGGTATCAGC
CATCACGCCGCCTCAGGCAATGGGACCAAACCTAGTCTTACCTGATCAGAAA
CCCCCATCCCGACAATCTCAAACAGAGTCCAAAGTGGCAACCCAGAGGCCCC
AAACGAATACAAGTACCCCAGGGTCTGTTGCCCCCGCCACCATGAGTCCCAA
ACGGATTGGGACCGGAGATAGGTTAATAAATTTAGTGCAAGGGACATACCTA
GCCTTAAATGCCACCGACCCCAACAAAACTAAAGACTGTTGGCTCTGCCTAG
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TTTCTCGACCACCCTATTACGAAGGGATGCAATCTTAGGTAACTACAGCAACC
AAACAAACCCCCCCCATCCTGCCTATCTACTCCGCAACATAAACTAACTATAT
CTGAGGTATCGGGGCAAGGACTGTGCATAGGGACTGTTCCTAAGACCCACCA
GG
Clone A4 Consensus Sequence

CCTTACTATAGGGCACGCGTGGTGGAATCCCACCTCCTCATGGGATTATATCA
CAGTAAAAAGAGGGAGTAGTCAGGACAATAGCTGCGAAAGAAAATGCAACC
CCCTAGTCTTACAGTTCACCCAGAAGGGAAGACAAGCCTCTTGGGACGGACC
TAAGATGTGGGGATTACGACTATACCGTACCGGATATGACCCTGTCACTTTAT
TCACGGTGTCCCGGCAGGTATCAGCCATCACGCCGCCTCAGGCAATGGGACC
AAACCTAGTCTTACCTGATCAGAAACCCCCATCCCGACAATCTCAAACAGAG
TCCAAAGTGGCAACCCAGAGGCCCCAAACGAATACAAGTACCCCAGGGTCTG
TTGCCCCCGCCACCATGAGTCCCAAACGGATTGGGACCGGAGATAGGTTAAT
AAATTTAGTGCAAGGGACATACCTAGCCTTAAATGCCACCGACCCCAACAAA
ACTAAAGACTGTTGGCTCTGCCTAGTTTCTCGACCACCCTATTACGAAGGGAT
TGCAATCTTAGGTAATTCCGCAACCAAACAAACCCCCCCCATCCTGCCTATCT
ACTCCGCAACATAAACTAACTATATCTGAGGTATCGGGGCAAGGACTGTGCA
TAGGGACTGTTCCTAAGACCCACCAGGCTAAGGG
Clone AS Consensus Sequence

GCGTGGTGGAATCCCACCTCCTCATGGGATTATATCACAGTAAAAAGAGGGA
GTAGTCAGGACAATAGCTGCGAAAGAAAATGCAACCCCCTAGTCTTACAGTT
CACCCAGAAGGGAAGACAAGCCTCTTGGGACGGACCTAAGATGTGGGGATf
ACGACTATACCGTACCGGATATGACCCTGTCACTTTATTCACGGTGTCCCGGC
AGGTATCAGCCATCACGCCGCCTCAGGCAATGGGACCAAACCTAGTCTTACC
TGATCAGAAACCCCCATCCCGACAATCTCAAACAGAGTCCAAAGTGGCAACC
AGAGGCCCCAAACGAATACAAGTACCCCAGGGTCTGTTGCCCCCGCCACCAT
GAGTCCCAAACGGATTGGGACCGGAAATAGGTTAATAAATTTAGTGCAAGGG
ACATACCTAGCCTTAAATGCCACCGACCCCAACAAAACTAAAGACTGTTGGC
TCTGCCTAGTTTCTCGACCACCCTATTACGAAGGGATTGCAATCTTAGGTAAC
TACAGCAACCAAACAAACCCCCCCCATCCTGCCTATCTACTCCGCAACATAA
ACTAACTATATCTGAGGTATCGGGGCAAGGACTGTGCATAGGGACTGTTCCT
AAGACCCACCAGG
Clone B1 Consensus Sequence

CCTCCATGGGAATATGATGACAGTGATTTAGACCTTGTGCAGAAACTTGAAG
CTCATTATGAGCCAAAAAGAGGTACCTGGGAGTACCAAGGGAAAACTATAAT
GCCTGAAAAATACGCAAAAGAGTTGATTAGCCATCTGCATAAGTTAACACAC
CTCAGTGCTAGGAAAATGAAAACTTTACTAGAAAGAGAAGAAACTGGGTTfT
23

ACCTCCCTAACAGAGACTTACACCTCCGGCAAGTAACAGAGAGCTGCCGGGC
ATGTGCTCAAATCAACGCAGGGAAGATAAAGTTTGGATCTGACGTAAGAGCC
CGAGGCCACCGGCCTGGAATACATTGGGAAGTAGACTTTACTGAAATCAAGC
CAGGAATGTATGGATATAAATACCTCTTGGTGTTCATAGATACCTTCTCTGGC
TGGGCCGAAGCTTACCCCGCCAAACATGAAACAGCAAAAGTTGTTGCCAAAA
AACTCTTAGAAGAAATTTTTCCTCGTTACGGGATCCCTCAGGTATTGGGTTCA
GATAATGGACCCGCCTTTATCTCCCAGGTAAGTCAGTCTGTGGCCACCCTACT
GGGGATTAATTGGAAATTACATTGTGCATACTGACCCCAAAGTTCAGGTCAA
GTAGAAAGAATGAATAGATCAATTAAAGAGACTTTAACTAAATTAACGCTAG
AAACTGGCTCTAGAGATTGGGTGCTCCTCCTGCCCCTTGTTTTATACCGGGTA
CGTAACACGCCAGGTCCTCACGGGTTAACTCCTTTTGAAATCCTGTACGGGGC
ACCCCCCACCTATGGCTCACTTCTTTGATGCTGATATCTCTAGCTTCGCTACTT
CCCCCACTATGCAGGCACATTTACGCGCCCTGCAGCTAGTCCAAGAAGAGAT
CCAGTGACCTCTAGCGGCGGCCTACCGAGAAAGGCTCGAGACCCCGATTGTG
TCTCACCCCTTCAAACCAGGAGACTCCGTCTGGGTTCGGAGACATCAAACCA
AGAACCTCGAGCCACGGTGGAAAGGACCACATATCGTCCTCCTGACCACCCC
CACAGCCTTAAAAGTAGACGGAGTTGCTGCTTGGATCCACGCCTCACATGTA
AAGGCTGCAGGGCCAACCACCAATCAGGACCCCTCAGACGACCCCAGCTCAA
ACGATCCATCGAGATGGAAGGTCCAACGCACCCAAAACCCTCTAAAGATAAG
ACTTTCTCGTGGGACCTAATGATTCTGGTGGGGGTCTTATTAAAACTAGACGT
GGGAATGGCCAATCCTAGTCCGCACCAAATATATAATGTAACTTGGGTAATA
ACCAATGTACAAACCAACACCCAAGCTAATGCCACCTCTATGCTAGGAACCT
TAACCGATGCCTACCCTACCCTACATGTTGACTTATGTGACCTAGTGGGAGAC
CCCTGGGAACCTATAGTCCTAGACCCAAACAATGTAAGACACGGGGCCCGTT
ATTCCTCCTCAAAATATGGATGTAAAACTACAGATAGAAAGAAACAGCAACA
GACATACCCCTTTTACGTCTGCCCAGGGCATGCCCCCGGAATGGGGCCAAAG
GGAACACATTGTGGAGGGGCACAAGATGGTTTTGTGCCGCTTGGGGATGTGA
AACCACAGGAGAAGCTTGGTGGAATCCCACCTCCTCATGGGATTATATCACA
GTAAAAAGAGGGAGTAGTCAGGACAATAGCTGCGAAAGAAAATGCAACCCC
CTAGTCTTACAGTTCACCCAGAAGGGAAGACAAGCCTCTTGGGACGGACCTA
AGATGTGGGGATTACGACTGTACCGTACCGGATATGACCCTGTCACTTTATTC
ACGGTGTCCCGGCAGGTATCAACCATCACGCCGCCTCAGGCAATGGGACCAA
ACCTAGTCTTACCTGATCAGAAACCCCCATCCCGACAATCTCAAACAGAGTC
CAAAGTGGCGACCAAAGTGGCAACCCAGAGGCCCCAAACGAATACAAGTAC
CCCAGGGTCTGTTGCCCCCGCCACCATGAGTCCCAAACGGATTGGGACCGGA
GATAGGTTAATAAATTTAGTGCAAGGGACATACCTAGCCTTAAATGCCACCA
ACCCCAACAAAACTAAAGACTGTTGGCTCTGCCTAGTTTCTCGACCACCCTAT
TACGAAGGGTTTGCAATCATAGGTAACTACAGCAACCAAACAAACCCCCCCC
CATCCTGCCTATCTACTCCGCAACATAAACTAACTATATCTGTGGTATCGGGG
CAAGGACTGTGCATAGGGACTGTTCCTAAGACCCACCAGG
Clone B2 Consensus Sequence

CTATAGGGCACGCGTGGTCGACGGCCCGGGCTGGTCCTCCATGGGAATATGA
TGACAGTGATTTAGACCTGGTGCAGAAACTTAAAGCTCATTATGAGCCAACA
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AGAGGCACCTGGGAGTACCAAGGGAAAACTATAATGCCTGAAAAATACGCG
AAAGAGTTGATTGGCCATCTGCATAAGTTAACACACCTCAGTGCAAAAAAAA
ATGAAAACTTTACTAGAAAGAGAAGAAACTGGGTTTTACCTTCCTAACAGAG
ACTTACACCTCCGGCAAGTAACAGAGAACTGCCGGGCATGTGCTCAAATCAA
CGCAGGGAAGATAAAGTTTGGATCTGACGTAAGAGCCCGGGGCCACCGGCCT
GGAATACATTGGGAAGTAGACTTTACTGAAATCAAGCCAGGAATGTATGGAT
ATAAATACCTCTTGGTGTTCATAGATACCTTCTCTGGCTGGGCCGAAGCTTAC
CCCGCCAAACATGAAACAGCAAAAGTTGTTGCCAAAAAACTCTTAGAAGAAA
TTTTTCCTCGTTACGGGATCCCTCAGGTATTGGGTTCAGATAATGGACCCGCC
TTTATCTCCCAGGTAAGTCAGTCTGTGGCCACCCTACTGGGGATTAATTGGAA
ATTACATTGTGCATACCGACCCCAAAGTTCAGGTCAAGTAGAAAGAATGAAT
AGATCAATTAAAGAGACTTTAACTAAATTAACGCTAGAAACTGGCTCTAGAG
ATTGGGTGCTCCTCCTGCCCCTTGTTTTATACCGGGTACGTAACACGCCAGGT
CCTCACGGGTTAACTCTTTTGAAATCCTGTACGGGGCACCCCCACCTATGGCT
CACTTCTTTTGATGCTGATATCTCTAGCTTCGCTACTTCCCCCACTATGCAGGC
ACATTTACGCGCCCTGCAGCTAGTCCAAGAAGAGATCCAGAGACCTCTAGCG
GCGGCCTACCGAGAAAGGCTCGAGACCCCGATTGTGCCTCACCCCTTCAAAC
CAGGAGACTCCGTCTGGGTTCGGAGACATCAAACCAAGAACCTCGAGCCACG
GTGGAAAGGACCACATATCGTCCTCCTGACCACCCCCACAGCCTTAAAAGTA
GACGGAGTTGCTGCTTGGATCCACGCCTCACATGTAAAGGCTGCAGGGCCAA
CCACCAATCAGGACCCCTCAGACGACCCCAGCTCAAACGATCCATCGAGATG
GAAGGTCCAACGCACCCAAAACCCTCTAAAGATAAGACTTTCTCGTGGGACC
TAATGATTCTGGTGGGGGTCTTATTAAGACTAGACGTGGGAATGGCCAATCC
TAGTCCGCACCAAATATATAATGTAACTTGGGTAATAACCAATGTACAAACC
AACACCCAAGCTAATGCCACCTCTATGCTAGGAACCTTAACCGATGCCTACC
CTACCCTACATGTTGACTTATGTGACCTAGTGGGAGACTCCTGGGAACCTATA
GTCCTAGACCCAAACAATGTAAGACACGGGGCCCGTTATTCCTCCTCAAAAT
ATGGATGTAAAACTACAGATAGAAAGAAACAGCAACAGACATACCCCTTTTA
CGTCTGCCCAGGGCATGCCCCCGGAATGGGGCCAAAGGGAACACATTGTGGA
GGGGCACAAGATGGGTTTTGTGCCGCTTGGGGATGTGAAACCACAGGAGAAG
CTTGGTGGAATCACACCTCCTCATGGGATTATATCACAGTAAAAAGAGGGAG
TAGTCAGGACAATAGCTGCGAAAGAAAATGGAAAGAAAATGCAACCCCCTA
GTCTTACAGTTCACCCAGAAGGGAAGACAAGCCTCTTGGGACGGACCTAAGA
TGTGGGGATTACGACTATACCGTACCGGATATGACCCTGTCACTTTATTCACG
GTGTCCCGGCAGGTATCAACCATCACGCCGCCTCAGGCAATGGGATCAAACC
TAGTCTTACCTGATCAGAAACCCCCATCCCGACAATCTCAAACAGAGTCCAA
AGTGGCGACCAAAGTGGCAACCCAGAGGCCCCAAACGAATACAAGTACCCC
AGGGTCTGTTGCCCCCGCCACCATGAGTCCCAAACGGATTGGGACCAGAGAT
AGGTTAATAAATTTAGTGCAAGGGACATACCTAGCCTTAAATGCCACCGACC
CCAACAAAACTAAAGACCGTTGGCTCTGCCTAGTTTCTCGACCACCCTATTAC
GAAGGGATTGCAATCTTAGGTAACTACAGCAACCAAACAAACCCCCCCCCAT
CCTGCCTATCTACTCCGCAACATAAACTAACTATATCTGAGGTATCGGGGCAA
GGACTGTGC
Clone B3 Consensus Sequence
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CCCTTACTATAGGGCACGCGTGGTCGACGGCCCGGGCTGGTCCTCCATGGGA
ATATGATGACAGTGATTTAGACCTGGTGCAGAAACTTAAAGCTCATTATGAG
CCAACAAGAGGCACCTGGGAGTACCAAGGGAAAACTATAATGCCTGAAAAA
TACGCGAAAGAGTTGATTGGCCATCTGCATAAGTTAACACACCTCAGTGCAA
AAAAAATGAAAACTTTACTAGAAAGAGAAGAAACTGGGTTTTACCTTCCTAA
CAGAGACTTACACCTCCGGCAAGCAACAGAGAGCTGCCGGGCATGTGCTCAA
ATCAACGCAGGGAAGATAAAGTTTGGATCTGACGTAAGAGCCCGAGGCCACC
GGCCTGGAATACATTGGGAAGTAGACTTTACTGAAATCAAGCCAGGAATGTA
TGGATATAAATACCTCTTGGTGTTCATAGATACCTTCTCTGGCTGGGCCGAAG
CTTACCCCGCCAAACATGAAACAGCAAAAGTTGTTGCCAAAAAACTCTTAGA
AGAAATTTTTCCTCGTTACGGGATCCCTCAGGTATTGGGTTCAGATAATGGAC
CCGCCTTfATCTCCCAGGTAAGTCAGTCTGTGGCCACCCTACTGGGGATTAAT
TGGAAATTACATTGTGCATACCGACCCCAAAGTTCAGGTCAAGTAGAAAGAA
TGAATAGATCAATTAAAGAGACTTTAACTAAACTAACGCTAGAAACTGGCTC
TAGAGATTGGGTGCTCCTCCTGCCCCTTGTTTTATACCGGGTACGTAACACGC
CAGGTCCTCACGGGTTAACTCCTTTTGAAATCCTGTACGGGGCACCCCCACCT
ATGGCTCACTTCTTTGATGCTGATATCTCTAGCTTCGCTACTTCCCCCACTATG
CAGGCACATTfACGCGCCCTGCAGCTAGTCCAAGAAGAGATCCAGAGACCTC
TAGCGGCGGCCTACCGAGAAAGGCTCGAGACCCCGATTGTGCCTCACCCCTT
CAAACCAGGAGACTCCGTCTGGGTTCGGAGACATCAAACCAAGAACCTCGAG
CCACGGTGGAAAGGACCACATATCGTCCTCCTGACCACCCCCACAGCCTTAA
AAGTAGACGGAGTTACTGCTTGGATCCACGCCTCACATGTAAAGGCTGCAGG
GCCAACCACCAATCAGGACCCCTCAGACGACCCCAGCTCAAACGATCCATCG
AGATGGAAGGTCCAACGCACCCAAAACCCTCTAAAGATAAGACTTTCTCGTG
GGACCTAATGATTCTGGTGGGGGTCTTATTAAGACTAGACGTGGGAATGGCC
AATCCTAGTCCGCACCAAATATATAATGTAACTTGGGTAATAACCAATGTAC
AAACCAACACCCAAGCTAATGCCACCTCTATGCTAGGAACCTTAACCGATGC
CTACCCTACCCTACATGTTGACTTATGTGACCTAGTGGGAGACTCCTGGGAAC
CTATAGTCCTAGACCCAAACAATGTAAGACACGGGGCCCGTTATTCCTCCTCA
AAATATGGATGTAAAACTACAGATAGAAAGAAACAGCAACAGACATACCCC
TTTfACGTCTGCCCAGGGCATGCCCCCGGAATGGGGCCAAAGGGAACACATT
GTGGAGGGGCACAAGATGGGTTTTGTGCCGCTTGGGGATGTGAAACCACAGG
AAAAGCTTGGTGGAATCCCACCTCCTCATGGGATTATATCACAGTAAAAAGA
GGGAGTAGTCAGGACGATAGCTGCGAAAGAAAATGCAACCCCCTAGTCTTAC
AGTTCACCCAGAAGGGAAGACAAGCCTCTTGGGACGGACCTAAGATGTGGG
GATTACGACTATACCGTACCGGATATGACCCTGTCACTTTATTCACGGTGTCC
CGGCAGGTATCAACCATCACGCCGCCTCAGGCAATGGGACCAAACCTAGTCT
TACCTGATCAGAAACCCCCATCCCGACAATCTCAAACAGAGTCCAAAGTGGC
GACCAAAGTGGCAACCCAGAGGCCCCAAACGAATACAAGTACCCCAGGGTC
TGTTGCCCCCGCCACCATGAGTCCCAAACGGATTGGGACCAGAGATAGGTTA
ATAAATTTAGTGCAAGGGACGTACCTAGCCTTAAATGCCACCGACCCCAACA
AAACTAAAGACTGTTGGCTCTGCCTAGTTTCTCGACCACCCTATTACGAAGGG
ATTGCAATCTTAGGTAACTACAGCAACCAAACTAACCCCCCCCCATCCTGCCT
ATCTACTCCGCAACATAAACTAACTATATCTGAGGTATCGGGGCAAGGACTG
TGCATAGGGACTGTTCCTAAGACCCACCAGGC
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Clone B4 Consensus Sequence

GAATGTATGGATATAAATACCTCTTGGTGTTCATAGACACCTTCTCTGGCTGG
GCCGAAGCTTACCCCGCCAAACATGAAACAGCAAAAGTTGTTGCCAAGAAAC
TCTTAGAAGAGATTTTTCCTCGTTACGGGATCCCTCAGGTATTGGGTTCAGAT
AATGGACCCGCCTTTATCTCCCAGGTAAGTCAGTCTGTGGCCACCCTACTGGG
GATTAATTGGAAATTACACTGTGCATACCGACCCCAAAGTTCAGGTCAGGTA
GAAAGAATGAATAGATCAATTAAGGAGACTTTAACTAAATTAACGCTAGAAA
CTGGCTCTAAGGATTGGGTGCTCCTCCTGCCCCTGGTTTTATACCGGGTACGT
AACACGCCAGGTCCCCACGGGTTAACTCCTTTTGAAATCCTGTACGGAGCAC
CCCCACCTATGGCTCACTTCTTTGATGCTGACATCTCTGGTTTCGCTACCTCCC
CCACCATGCAGGCACATTTACGCGCCCTGCAGCTGGTTCAAGAAGAGATCCA
GAGACCTCTAGCGGCAGCCTACCGAGAAAAGCTCGAAACCCCGGTTGTGCCT
CACCCCTTCAAACCAGGAGACTCCGTCTGGGTTCGGAGACATCAAACCAAGA
ACCTCGAGCCACGGTGGAAGGGACCACATATCGTCCTCCTGACCACCCCCAC
GGCCTTAAAAGTAGACGGAGTTGCTGCTTGGATCCACGCCTCACATGTAAAG
GCTGCAGGGCCAACCACCAATCAGGACCCCTCAGACGACCCCAGCTCAGACG
ATCCATCGAGATGGAAGGTCCAACGCACCCAAAACCCTCTAAAGATAAGACT
TTCTCGTGGGACCTAATGATTCTGGTGGGGGTCTTATTAAGACTAGACGTGGG
AATGGCCAATCCTAGTCCGCACCAAATATATAATGTAACTTGGGTAATAACC
AATGTACAAACCAACACCCAAGCTAATGCCACCTCTATGCTAGGAACCTTAA
CCGATGCCTACCCTACCCTACATGTTGACTTATGTGACCTAGTGGGAGACTCC
TGGGAACCTATAGTCCTAGACCCAAACAATGTAAGACACGGGGCCCGTTATT
CCTCCTCAAAATATGGATGTAAAACTACAGATAGAAAGAAACAGCAACAGA
CATACCCCTTTTACGTCTGCCCAGGGCATGCCCCCGGAATGGGGCCAAAGGG
AACAAATTGTGGAGGGGCACAAGATGGGTTTTGTGCCGCTTGGGGATGTGAA
ACCACAGGAGAAGCTTGGTGGAATCCCACCTCCTCATGGGATTATATCACAG
TAAAAAGAGGGAGTAGTCAGGACAATAGCTGCGAAAGAAAATGCAACCCCC
TAGTCTTACAGTTCACCCAGAAGGGAAGACAAGCCTCTTGGGACGGACCTAA
GATGTGGGGATTACGACTATACCGTACCGGATATGACCCTGTCACTTTATTCA
CGGTGTCCCGGCAGGTATCAACCATCACGCCGCCTTCAGGCAATGGGACCAA
AACCTAGTCTTACCTGATCAGAAACCCCCATCCCGACAATCTCAAACAGAGT
CCAAAGTGGCAACCCAGAGGCCCCAAACGAATACAAGTACCCCAGGGTCTGT
TGCCCCCGCCACCATGAGTCCCAAACGGATTGGGACCGGAGATAGGTTAATA
AATTTAGTGCAAGGGACATACCTAGCCTTGAATGCCACCGACCCCAACAAAA
CTAAAGACTGTTGGCTCTGCCTAGTTTCTCGACCACCCTATTACGAAGGGATT
GCAATCTTAGGTAACTACAGCAACCAAACAAACCCCCCCCATCCTGCCTATC
TACTCCGCAATAAACTAACTATATCTGAGGTATCGGGGCAAGGACTGTGCAT
AGGGAGTGTTCCTAAGACCCACCAG
Clone B5 Consensus Sequence
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TACTATAGGGCACGCGTGGTCGACGGCCCGGGTTTGGTCCTCCATGGGAATA
TGATGACAGTGATTfAGACCTTGCTGCAGAAACTTGAAGCTCATTATGAGCC
AAAAAGAGGTACCTGGGAGTACCAAGGGAAAACTATAATGCCTGAAAAATA
CGCAAAAGAGTTGATTAGCCATCTGCATAAGTTAACACACCTCAGTGCTAGG
AAAATGAAAACTTTACTAGAAAGAGAAGAAACTGGGTTTTACCTCCCTAACA
GAGACTTACACCTCCGGCAAGTAACAGAGAGCTGCCGGGCATGTGCTCAAAT
CAACGCAGGGAAAATAAAGTTTGGACCTGATGTAAGGGCCCGAGGCCACCG
GCCCGGAATACATTGGGAAGTAGACTTCACTGAAATCAAGCCAGGAATGTAT
GGATATAAATACCTCTTGGTGTTCATAGACACCTTCTCTGGCTGGGCCGGAGC
TTACCCCGCCAAACATGAAACAGCAAAAGTTGTTGCCAAGAAACTCTTAGAA
GAGATTTTTCCTCGTTACGGGATCCCTCAGGTATTGGGTTCAGATAATGGACC
CGCCTTTATCTCCCGGGTAAGTCAGTCTGTGGCCACCCTACTGGGGATTAATT
GGAAATTACATTGTGCATACCGACCCCAAAGTTCAGGTCAGGTAGAAAGAAT
GAATAGATCAATTAAGGAGACTTTAACTAAATTAACGCTAGAAACTGGCTCT
AAGGATTGGGTGCTCCTCCTGCCCCTGGTTTTATACCGGGTACGTAACACGCC
AGGTCCCCACGGGCTTAACTCCTTTTGAAATCCTGTACGGAGCACCCCCACCT
ATGGCTCACTTCTTTGATGCTGACACCTCTGGTTTCGCTACCTCCCCCACCAT
GCAGGCACATTTGCGCGCCCTGCAGCTAGTCCAAGAAGAGATCCAGAGACCT
CTAGCGGCGGCCTACCGAGAAAGGCTCGAGACCCCGATTGTGCCTCACCCCT
TCAAACCAGGAGACTCCGTCTGGGTTCGGAGACATCAAACCAAGAACCTCGA
GCCACGGTGGAAAGGACCACATATCGTCCTCCTGACCACCCCCACAGCCTTA
AAAGTAGACGGAGTTGCTGCTTGGATCCACGCCTCACATGTAAAGGCTGCAG
GGCCAACCACCAATCAGGACCCCTCAGACGACCCCAGCTCAAACGATCCATC
GATGGAAGGTCCAACGCACCCAAAACCCTCTAAAGATAAGACTTTCTCGTGG
GACCTAATGATTCTGGTGGGGGTCTTATTAAGACTAGACGTGGGAATGGCCA
ATCCTAGTCCGCACCAAATATATAATGTAACTTGGGTAATAACCAATGTACA
AACCAACACCCAAGCTAATGCCACCTCTATGCTAGGAACCTTAACCGATGCC
TACCCTACCCTACATGTTGACTTATGTGACCTAGTGGGAGACTCCTGGGAACC
TATAGTCCTAGACCCAAACAATGTAAGACACGGGGCCCGTTATTCCTCCTCA
AAATATGGATGTAAAACTACAGATAGAAAGAAACAGCAACAGACATACCCC
TTTTACGTCTGCCCAGGGCATGCCCCCGGAATGGGGCCAAAGGGAACAAATT
GTGGAGGGGCACAAGATGGGTTTTGTGCCGCTTGGGGATGTGAAACCACAGG
AGAAGCTTGGTGGAATCCCACCTCCTCATGGGATTATATCACAGTAAAAAGA
GGGAGTAGTCAGGACAATAGGTGCGAAAGAAAATGCAACCCCCTAGTCTTAC
AGTTCACCCAGAAGGGAAGACAAGCCTCTTGGGACGGACCTAAGATGTGGG
GATTACGACTATACCGTACCGGATATGACCCTGTCACTTTATTCACGGTGTCC
CGGCAGGTATCAACCATCACGCCGCCTCAGGCAATGGGACCAAACCTAGTCT
TACCTGATCAGAAACCCCCATCCCGACAATCTCAAACAGAGTCCAAAGTGGC
AACCCGGAGGCCCCAAACGAATACAAGTACCCCAGGGTCTGTTGCCCCCGCC
ACCATGAGTCCCAAACGGATTGGGACCGGAGATAGGTTAATAAATTTAGTGC
AAGGGACATACCTAGCCTTAAATGCCACCGACCCCAACAAAACTAAAGACTG
TTGGCTCTGCCTAGTTTCTCGACCACCCTATTACGAAGGGATTGCAATCTTAG
GTAACTACAGCAACCAAACAAACCCCCCCCCATCCTGCCTATCTACTCCGCA
ACATAAACTAACTATATCTGAGGTATCGGGGCAAGGACTGTGCATAGGGACT
GTTCCTAAGACCCACCAGGCTAAGGG
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